<DOC>
	<DOCNO>NCT02103465</DOCNO>
	<brief_summary>This exploratory trial fulfill medical data gap dopamine-agonist rotigotine , far data elderly population available . Primary objective : To assess efficacy safety rotigotine patient late onset Parkinson 's Disease ( PD ) , start age 70 later , motor symptom . Secondary objective : To assess efficacy safety rotigotine patient late onset Parkinson 's Disease ( PD ) , start age 70 later , select non motor symptom : sleep quality ; depression ; cognitive function . Subjects ≥70 year , diagnosis Parkinson 's Disease ( PD ) base presence least two three cardinal feature ( bradykinesia , rest tremor , rigidity ) , within 12 month since diagnosis longer 12 month onset diagnosis , care physician uncertain whether start treatment . Outcome Measurement : Percentage Responders treatment motor ( part III ) Activities daily live ( ADL ) ( part II ) component Unified Parkinson 's Disease Rating Scale ( UPDRS ) visit 4 6 ; Percentage Responders treatment sleep quality relation Parkinson 's Disease Sleep Scale ( PDSS ) -2 visit 4 6 ; Responders treatment mood relation Geriatric Depression Scale ( GDS ) visit 4 6 . Exploratory , randomize , double blind , placebo-controlled study : 80 patient late onset Parkinson 's Disease ( PD ) randomize 2 parallel group , ratio 1:1 . One group treat rotigotine one group treat placebo , 12 week titration .</brief_summary>
	<brief_title>Possible Use Rotigotine Subjects 70 Years Older With Late Onset Disease</brief_title>
	<detailed_description>Treatment titrate optimal dose ( investigator subject felt motor non motor impairment adequately control ) , start 2 mg/24 hr increase weekly increment 2 mg/24 hr maximum 8 mg/24 hr . The dose maintain optimal maximal dose 8-week period ( maintenance period ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Age ≥70 year Idiopathic Parkinson 's Disease ( PD ) confirm least two follow sign : rest tremor , bradykinesia , rigidity Diagnosis Parkinson 's Disease ( PD ) within last 12 month onset symptom within 12 month diagnosis Disease stage I II accord Hoehn Yahr Scale Ability provide write informed consent Patients willing able comply schedule visit , treatment plan , laboratory test study procedure Disease duration 12 month since diagnosis and/or duration symptom diagnosis 12 month Hoehn &amp; Yahr stage ≥3 Atypical secondary parkinsonism Patient currently Ldopa , Dopamine Agonist ( DA ) Parkinson 's Disease ( PD ) medication baseline Centrally act dopaminergic agent , monoamine oxidase inhibitor ( MAOIs ) , tolcapone , budipine , neuroleptic take within 28 day precede baseline visit History deep brain stimulation History severe cardiac disease/heart failure last 3 year History repeat fall History sulfite sensitivity Arterial hypotension Stroke transient ischemic attack within last 12 month Previous current treatment rotigotine ( time ) Diagnosis dementia accord Diagnostic Statistic Manual ( DSM ) IVRevised Mini Mental State Examination ( MMSE ) total score &lt; 24 screen visit History psychosis Clinically relevant hepatic dysfunction and/or transaminase level 5+ time high upper normal value Experimental treatment within antecedent 3 month History drug alcohol dependency Poor compliance treatment Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>treatment</keyword>
	<keyword>old patient</keyword>
	<keyword>Rotigotine</keyword>
</DOC>